Is Compounded Semaglutide Still Legal in 2026? What the Shortage Ruling Changed

Written by the Weight Loss Reviewed editorial team · Reviewed October 2026. This is general information about a fast-moving regulatory situation, not legal or medical advice — verify current status with the FDA and a licensed professional.

If you bought compounded semaglutide online in 2023 or 2024, you did something that was, at the time, broadly permitted — and is now a much grayer area. The legal ground under compounded GLP-1 medications shifted hard between late 2024 and 2026, and a lot of the information floating around is either out of date or written by someone trying to sell you something. This guide is the plain-English, sourced version of what actually changed, what's still allowed, and how to tell a legitimate compounded-GLP-1 program from one that's cutting corners you'll regret.

We'll be precise about what is settled and what is still moving, because this is a situation where the details decide whether something is legal, risky, or neither. Where a fact comes from the FDA or a regulator, we say so and link it. Where the answer is "it depends" or "it's being litigated," we say that too, rather than rounding up to a cleaner story. This is not legal advice, and it is not medical advice — it's a map, and the territory is changing, so we'll point you to the primary sources you can check yourself.

Is compounded semaglutide legal in 2026? The direct answer

Here's the honest, unspun version. Compounded semaglutide and tirzepatide are no longer legal the way they were during the shortage — the broad permission that let pharmacies and outsourcing facilities mass-produce low-cost copies for anyone with a prescription has ended, because that permission existed only while the brand-name drugs were in official shortage, and they no longer are.

But "no longer legal the way it was" is not the same as "illegal." Compounding is a long-standing, legitimate part of pharmacy, and there remains a narrow, legal path: a traditional (503A) compounding pharmacy can prepare semaglutide or tirzepatide for a specific patient, with a valid prescription, when the compounded version is not simply a copy of the commercial drug — for example, when a patient needs a strength that isn't commercially available, or can't tolerate an ingredient in the FDA-approved product. That path is real, but it is much smaller than the "everyone gets cheap compounded semaglutide" model that defined 2023–2024, and crucially, wanting to pay less is not, by itself, a legal basis for compounding.

So the accurate one-sentence answer is: compounded GLP-1s can still be dispensed legally in specific, patient-individualized circumstances through a licensed pharmacy, but the cheap, mass-market, one-size-fits-all version lost its legal footing when the shortage ended, and the companies still selling that way are relying on an argument the FDA is actively challenging. The rest of this guide unpacks exactly what that means for you as a buyer — and the table a few sections down shows which pathways are solid and which are shaky at a glance.

One more framing point before the detail: this is a fast-moving regulatory and legal situation. Dates, deadlines and a pending FDA rule all feature below, and any of them can change. We give you the state of play as of 2026 and, more importantly, we show you how to check the current status yourself — because in this topic, a six-month-old answer can be wrong.

How we got here: the shortage, the boom, and the end of the exemption

To understand why the legal status flipped, you have to understand the strange window that created the compounded-GLP-1 industry in the first place. It wasn't a loophole exactly — it was a deliberate, temporary feature of U.S. drug law that got enormous.

The rule that opened the door

Normally, pharmacies are not allowed to mass-produce copies of a commercially available, FDA-approved drug. That would undercut the entire approval system. But federal law carves out compounding — the practice of a pharmacy preparing a customized medication for a patient — and one of the specific situations where compounding a version of an approved drug is permitted is when that drug is on the FDA's official shortage list. The logic is humane: if patients can't get the real thing because it's unavailable, a compounding pharmacy can help fill the gap.

When Wegovy, Ozempic, Mounjaro and Zepbound exploded in demand, the brand manufacturers couldn't keep up, and semaglutide and tirzepatide landed on the FDA shortage list. That switched on the shortage exemption — and an entire industry of telehealth companies and compounding pharmacies rushed in to sell compounded semaglutide and tirzepatide at a fraction of the brand price. For a couple of years, that was broadly permitted. The FDA's own compounding Q&A lays out the framework that made it possible.

The shortage ends — and so does the exemption

The exemption was always tied to the shortage, and shortages end. As the manufacturers scaled up production, the FDA determined the drugs were available again: it declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. Once a drug comes off the shortage list, the shortage-based reason to compound copies of it goes away.

The FDA didn't flip a switch overnight; it gave compounders wind-down periods to stop. For semaglutide, traditional 503A pharmacies were generally given until around April 22, 2025, and larger 503B outsourcing facilities until around May 22, 2025, to stop compounding essentially-copies; tirzepatide's deadlines came earlier in 2025. After those dates, continuing to mass-produce compounded copies on the old basis was no longer covered. You can confirm whether any drug is currently in shortage on the FDA's drug shortages database — the single most useful bookmark for anyone tracking this.

Why you still see compounded GLP-1s everywhere

If the exemption ended in 2025, why are telehealth ads for cheap compounded semaglutide still all over your feed? Three reasons, and they matter for judging what you're being sold. First, some operators pivoted to the narrow patient-specific "personalization" argument (more on that below) to keep going. Second, some are simply betting that enforcement is slower than the rule, and are continuing in a gray zone. Third, some are selling outright non-compliant or unsafe products — including "research peptides" that were never legal to use as medicine at all. The surface looks the same as it did in 2024; the legal reality underneath it is very different, and part of the job of this guide is helping you tell those three apart.

The timeline at a glance

For a situation this fast-moving, a dated sequence is clearer than prose. Here's how the compounded-GLP-1 picture got to where it is — approximate dates, because some played out over weeks and a few specifics are still contested.

• 2021–2022: Wegovy and the other GLP-1 brands launch and demand explodes. Manufacturers can't keep up; semaglutide and tirzepatide land on the FDA shortage list, switching on the shortage-based compounding exemption.
• 2022–2024: The compounded-GLP-1 boom. Telehealth companies and compounding pharmacies sell low-cost compounded semaglutide and tirzepatide at scale, broadly permitted because the drugs are officially in shortage.
• October–December 2024: Supply catches up. The FDA moves tirzepatide off the shortage list and, after a brief reconsideration, confirms the tirzepatide shortage resolved (December 2024).
• February 2025: The FDA declares the semaglutide shortage resolved, removing the shortage-based basis for compounding it.
• Early 2025: The Outsourcing Facilities Association sues the FDA to challenge the shortage-resolution decisions. The courts side with the FDA; the wind-down deadlines hold.
• Spring 2025: Wind-down deadlines take effect — for semaglutide, roughly 503A pharmacies by April 22, 2025 and 503B facilities by May 22, 2025; tirzepatide's deadlines fall earlier. Mass compounding of essentially-copies is no longer covered.
• Mid–late 2025: Many telehealth operators pivot to a "personalized" 503A framing to keep selling. State boards of pharmacy issue compliance alerts. New lawsuits target the medical-necessity rationale.
• April 2026: The FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, which would further restrict outsourcing-facility compounding. A public comment period follows.
• Mid–late 2026: The comment period closes; a final determination is pending. The narrow 503A patient-specific pathway remains; the mass-market model stays under pressure.

The shape of that timeline is the whole argument in miniature: a temporary permission, switched on by a shortage, that got huge — and then switched off when the shortage ended, with the industry fighting a losing rearguard action and regulators steadily tightening. Anyone telling you compounded GLP-1s are in exactly the same position they were in 2023 either hasn't followed the sequence or is hoping you haven't.

503A vs 503B: the two kinds of compounding, and why the difference decides legality

Almost every confused argument about "is it legal" comes from blurring two very different kinds of compounding. Get this distinction straight and most of the fog clears.

503A — traditional pharmacy compounding

A 503A pharmacy is a traditional compounding pharmacy that prepares a customized medication for a specific, named patient in response to a valid individual prescription. This is the old, legitimate heart of compounding: a pharmacist making a tailored preparation a particular person needs. Under the law, a 503A pharmacy may compound a drug that's essentially a copy of a commercially available product only in limited situations — and absent a shortage, the key one is that the prescriber has determined the compounded product will produce a significant difference for that specific patient compared with the approved drug. A different strength the manufacturer doesn't sell, or removing an ingredient the patient is allergic to, can qualify. A lower price cannot.

503B — outsourcing facilities

A 503B outsourcing facility is a larger operation that can manufacture compounded drugs in bulk, often without a patient-specific prescription, and sell them to clinics and providers. 503B facilities operate under stricter manufacturing standards, but they face tight limits on compounding copies of approved drugs, and they may only compound from bulk substances on a specific FDA list (the "503B bulks list"). During the shortage, 503B facilities were a major engine of cheap compounded GLP-1 supply. With the shortage over, that engine is largely shut off — and, as we'll see, the FDA has proposed to close it further.

The FDA's human drug compounding framework is the authoritative reference for both categories. The practical upshot for a buyer: the only remaining broadly-legal route for a compounded GLP-1 runs through a 503A pharmacy, a real prescription, and a genuine patient-specific clinical reason — not through a bulk outsourcing operation selling the same formula to everyone.

The "personalization" pathway — and why it's contested

Here is where the current fight actually lives, and where a careful buyer earns their safety. After the shortage ended, many telehealth companies didn't shut down their compounded GLP-1 lines — they reframed them. Instead of "compounded semaglutide because it's in shortage," the pitch became "personalized semaglutide," often by adding another ingredient (vitamin B12 is the classic example), or by prescribing non-standard doses, to argue the product isn't just a copy of Wegovy but a customized preparation that qualifies under the 503A patient-specific exception.

Is that legal? Sometimes, genuinely — and sometimes it's a fig leaf. The law does allow a 503A pharmacy to compound a patient-specific preparation that differs meaningfully from the commercial product when a prescriber documents a real clinical need. If you truly can't tolerate something in the approved drug, or need a strength that doesn't exist commercially, that's the system working as intended. The problem is that adding a splash of B12 to semaglutide and calling it "personalized" for hundreds of thousands of identical customers is a much weaker version of that argument — and the FDA has signaled it does not consider trivial tweaks, or "cheaper," to be legitimate grounds for compounding a copy.

This isn't just a theoretical dispute. The compounding industry challenged the FDA's shortage-resolution decisions in federal court, and the courts sided with the FDA; the wind-down deadlines held. Separately, legal challenges have targeted the "medical necessity" basis some compounders rely on, directly attacking whether the personalization claims are legitimate. The direction of travel is unmistakable: regulators and courts are tightening, not loosening. So when you see a flat-rate "personalized" compounded GLP-1 sold to the masses, understand what you're looking at — a business model leaning on a contested legal argument, not a settled green light. The FDA's own warnings about unapproved GLP-1 drugs are worth reading before you decide that's a risk you want.

The pathways compared: what's solid, what's shaky, what's dangerous

This is the whole landscape in one view. Use it to place any offer you're considering into the right row before you judge it.

General guidance as of 2026, not legal advice. Status is moving — verify current FDA shortage status and the specific pharmacy's licensing before relying on any row. "Essentially a copy" sold purely to save money does not qualify for the 503A exception.

What's still undecided: the 503B bulks-list proposal and the courts

Two moving pieces could tighten things further, and an honest guide flags them rather than pretending the dust has settled.

The 503B bulks-list proposal. In April 2026, the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the list of bulk drug substances that 503B outsourcing facilities are allowed to compound from. In plain terms: if finalized, that would further shut the door on bulk-compounded GLP-1s by removing the raw-material permission at the outsourcing-facility level. The proposal went through a public comment period in mid-2026, and as of this writing a final determination is still pending. If you're relying on a 503B-sourced product, this is the development to watch.

The litigation. The Outsourcing Facilities Association, representing compounders, challenged the FDA's shortage-resolution decisions in federal court. The courts did not reverse the FDA — the agency's determinations and the compounding wind-down deadlines held. Additional lawsuits have since targeted the medical-necessity rationale behind some compounded prescriptions. None of this is a final, permanent settlement of every question, and appeals and new cases can shift details, but the pattern across both the regulatory and the legal fronts points the same way: toward tighter limits on compounded GLP-1s, not looser ones.

The practical takeaway from the "undecided" column: don't build your long-term plan around the cheap compounded route being stable. It may persist in the narrow legitimate form, but the mass-market version is being squeezed from several directions at once, and a program that's cheap today because of a contested legal position may not be able to keep that up.

The enforcement reality: rule vs practice

There's a gap between what the rule says and what gets enforced, and understanding it is the difference between judging your own risk sensibly and either panicking or ignoring the issue. Both extremes are wrong.

The rule is clear enough: with the shortage over, broadly compounding essentially-copies of semaglutide and tirzepatide is no longer covered, and only narrow patient-specific compounding remains. Enforcement, though, is a different machine. The FDA and state boards have finite resources, enforcement tends to move slower than the underlying rule, and the agency generally works through warning letters, inspections and escalating action rather than overnight shutdowns. That lag is exactly why you still see so many compounded-GLP-1 ads: some operators are continuing in the gap between "no longer clearly permitted" and "actively stopped."

What does that mean for you, practically? Two things, pulling in opposite directions. On one hand, the sky isn't falling tomorrow — a legitimate 503A program with a real clinical basis isn't going to vanish overnight, and plenty of people will keep getting compounded GLP-1s through 2026 without incident. On the other hand, "they haven't been stopped yet" is not the same as "this is solidly legal," and a business model that depends on enforcement staying slow is not one to build your long-term health plan around. The warning letters and the pending bulks-list rule are the FDA signaling intent; the direction is set even if the timeline is gradual.

The sensible reading is neither "it's illegal, run" nor "nothing's changed, carry on." It's: the legitimate narrow path is fine, the mass-market path is living on borrowed time, and your job as a buyer is to make sure you're on the former and not the latter — and to have a plan B (a legitimate branded route you've already priced) in case your provider's model catches up with the rule. People who get caught out won't be the ones who understood the risk; they'll be the ones who assumed 2023 rules still applied.

Compounded vs branded in 2026: the honest decision

Set the legal question aside for a moment and look at this as a consumer decision, because the two questions have converged: the thing that's more legally solid is now also, for a lot of people, the better practical buy. Here's the real comparison across the dimensions that actually matter.

Price — the gap that shrank

Price was the whole reason compounded took off. During the shortage, compounded semaglutide could cost a fraction of the branded list price, and when the branded drug was also just unavailable, the choice made itself. In 2026 that calculus has shifted twice: the branded makers introduced lower-cost, direct-to-patient self-pay options, and the compounded route carries new legal and supply risk. The gap is no longer the chasm it was. For some people compounded is still cheaper month to month; for others, once you account for consistency and the risk of a program folding, the FDA-approved drug at a manufacturer-direct price is the better deal. The only way to know is to price your specific situation today — not from a 2023 memory.

Quality and oversight — not a close call

This one isn't balanced. Branded Wegovy, Zepbound, Ozempic and Mounjaro are FDA-approved: manufactured to approved standards, tested, consistent dose to dose. Compounded products are not FDA-approved and don't go through premarket review, so quality rides entirely on the specific pharmacy, and the FDA has documented real problems — dosing errors, different salt forms, mislabeled sourcing. A great compounding pharmacy narrows this gap; a bad one makes it a canyon, and you can't always tell from the website. If consistency and oversight matter to you, branded wins cleanly.

Dosing format — pens vs vials

Branded products come as fixed-dose pens or pre-measured injectors designed so you can't easily take the wrong amount. Compounded products often come as vials you draw up yourself, which is exactly where the FDA's documented overdoses happened. For someone comfortable and careful with a syringe, that's manageable; for a lot of people, the pen's built-in safety margin is worth real money.

Supply stability — the new tiebreaker

Here's the dimension almost nobody weighed in 2023 and everyone should weigh now. A GLP-1 is, for most people, a long-term medication. Branded supply is stable and legal. The cheap compounded route is legally contested and under active tightening, which means a nonzero chance your program has to stop offering it, or changes your formula, mid-treatment. Interruptions to a GLP-1 aren't trivial — appetite and weight tend to rebound. Building a long-term plan on a shrinking legal basis is a real downside that a slightly lower monthly price may not offset.

When compounded still makes sense

None of this means compounded is never the right call. For a patient with a genuine, documented clinical reason the commercial product doesn't work — a true allergy to an excipient, a need for a dose that isn't manufactured — the 503A pathway exists precisely for that, and it can be both legal and the best clinical option. And for some people without insurance coverage, a legitimate compounded program may still be the most affordable route to treatment at all. The decision isn't "compounded bad, branded good"; it's that the defaults flipped. In 2023, compounded was the obvious value play. In 2026, branded through an affordable legitimate channel is the sensible default, and compounded is the considered exception for people with a specific reason.

Beyond legal: the safety questions that matter just as much

Legality and safety are related but not the same, and for a drug you inject into your body weekly, safety deserves its own hard look. Even a compounded product dispensed through a legitimate 503A pathway is not the FDA-approved drug, and that difference is not a technicality.

Compounded drugs are not FDA-approved, and don't go through premarket review. The FDA is explicit about this: compounded medications do not undergo the agency's review for safety, effectiveness or manufacturing quality before they reach you. Quality therefore rides entirely on the specific pharmacy — its sourcing, its sterility, its testing. A good compounding pharmacy produces a clean, correctly-dosed product; a bad one is a real hazard, and you often can't tell which is which from a slick website.

The FDA has documented concrete harms. This isn't hypothetical. The agency has warned about dosing errors with compounded semaglutide — people drawing up the wrong amount and overdosing, sometimes landing in the emergency room, because compounded products come in varied concentrations and formats rather than a standardized pen. It has also raised broader concerns about unapproved GLP-1 products, including the use of different salt forms of the active ingredient that aren't the same as what's in the approved drugs, and fake or mislabeled sourcing.

What real buyers report. Look across the public reviews and community discussions for compounded-GLP-1 telehealth programs and a consistent pattern emerges, alongside the many people who report smooth experiences and real weight loss. The recurring complaints cluster around: confusion over dosing with vials and syringes versus the familiar pens; inconsistent product between refills or pharmacies; shipping delays and cold-chain worries; and difficulty reaching a human when something goes wrong. None of that means compounded is uniformly bad — plenty of people use it without incident — but the complaint pattern maps almost exactly onto the safety gaps the FDA names, which is worth taking seriously rather than dismissing as internet noise.

Who compounded GLP-1s are NOT for

Most guides on this topic are busy selling you something, so they skip this part. We won't. There are people for whom chasing a compounded GLP-1 in 2026 is the wrong move, and naming them plainly is more useful than a blanket "it's great."

• Anyone being offered it with no real prescription or medical review. If a site will sell you an injectable GLP-1 without a genuine clinical evaluation by a licensed prescriber, stop. That's the brightest red line there is — it's both the biggest safety risk and the clearest sign of an operation you don't want handling your health.
• People drawn in purely by price who could access the branded drug. If you can get FDA-approved Wegovy or Zepbound through insurance, a manufacturer savings program, or the manufacturers' own lower-cost direct options, the small price gap may not be worth trading away FDA oversight, consistent dosing and a known safety profile. "Cheaper" is exactly the reason that does not justify compounding legally — and often isn't worth it practically either.
• Anyone uncomfortable self-managing dosing from a vial. Much of the documented harm comes from drawing up the wrong dose. If you want the simplicity and safety margin of a fixed-dose pen, the branded products are built for that; compounded vials ask more of you.
• People who need certainty and stability. If a reliable, uninterrupted long-term supply matters to you — and for a chronic-condition medication it should — building your plan on a product whose legal footing is contested and shrinking is a shaky foundation. You may be fine; you may also get a "we can no longer offer this" email.
• Anyone tempted by "research peptides" or no-prescription overseas sources. This isn't a budget version of the same thing. It's unregulated material of unknown identity, purity and sterility, with no oversight and no recourse. The honest advice is simply: don't.

If you're in one of those groups, the better move is almost always to pursue the FDA-approved drug through the most affordable legitimate channel, which we cover next. If you're not — if you have a genuine, documented reason the commercial product doesn't work for you — then the narrow 503A pathway exists for exactly your situation, and the key is choosing the pharmacy and program carefully.

What people actually report: the community picture

Regulatory analysis tells you what's allowed; it doesn't tell you what the experience is actually like. Reading across public reviews, ratings and community discussions for compounded-GLP-1 programs surfaces consistent patterns worth knowing — presented here as aggregated sentiment, not cherry-picked quotes, and balanced between the genuinely positive and the recurring complaints.

The positive patterns are real and common. A large share of people report exactly what drew them in: meaningful weight loss, a price that made treatment affordable when the branded drug wasn't, and a fast, low-friction sign-up. For people who couldn't otherwise access a GLP-1 at all, legitimate compounded programs genuinely opened a door, and plenty report months of smooth refills and good results. It would be dishonest to pretend the whole category is a disaster; for many users it worked.

The complaint patterns are just as consistent — and they track the risks. The recurring negatives cluster into a few themes that show up again and again across programs. Dosing confusion leads: people used to a fixed-dose pen find vials-and-syringes genuinely confusing, and uncertainty about "how many units" is a frequent, worrying refrain — which lines up precisely with the FDA's documented dosing-error harms. Product inconsistency comes next: reports of the formula, concentration or supplying pharmacy changing between refills, which rattles people reasonably. Shipping and cold-chain anxiety is common — delays, warm packages, questions about whether the product was handled correctly. And support friction rounds it out: difficulty reaching a real clinician or getting a straight answer when something seems off.

A newer pattern: legal-status anxiety. Since the shortage ended, community discussion increasingly features people worried about whether their program is still legitimate, confused about "personalized" framing, or reporting that a provider changed its offering or pricing. That anxiety is rational, and it's a sentiment signal in its own right: the users themselves can feel the ground shifting.

The honest synthesis: compounded GLP-1s have worked well for a lot of people and badly for a meaningful minority, and the bad experiences cluster exactly where the structural risks are — dosing, consistency, handling and support. That's not a reason to dismiss the category, but it is a reason to weight those specific risks heavily when you choose, and to treat a program's handling of dosing clarity and customer support as a real quality signal, not an afterthought. Where we have verified aggregate review data for specific programs, we publish it on each provider's review page rather than generalizing.

How to vet a compounded-GLP-1 program (if you go that route)

Suppose you've weighed it and a compounded GLP-1 through a legitimate route makes sense for you. Here's how to separate a responsible 503A-based program from a gray-zone operation, before you hand over a card number.

• Confirm there's a real prescription and a real clinician. A legitimate program requires a genuine medical intake reviewed by a licensed prescriber, and you can find out who is prescribing and reach them with questions. "Guaranteed approval" or "no prescription needed" is disqualifying.
• Ask which pharmacy fills it — and verify it. A responsible program names its pharmacy partner. You can then check that pharmacy's license with the relevant state board of pharmacy, and confirm it's a properly licensed 503A (or 503B) facility in good standing. A program that won't tell you where your medication is made is telling you something.
• Understand the legal basis they're using. Is this a genuine patient-specific compound for a documented clinical reason, or a mass-market "personalized" formula sold to everyone at a flat price? The latter is the contested model. You're allowed to ask directly why they can legally compound it for you.
• Scrutinize the dosing format. Will you get clear, unambiguous dosing instructions, in a format you're comfortable measuring? Given the FDA's documented dosing-error harms, this is a safety question, not a convenience one.
• Read the pricing like a hawk. Suspiciously low flat rates, "research" framing, or pressure to prepay for many months are warning signs. Our guide to what you'll really pay and our ranked comparison show how to compare the real monthly cost honestly.
• Keep your own records. Save what you're prescribed, the concentration, the pharmacy, and your clinician contacts. If anything goes wrong, or the product changes between refills, you'll want that trail.

Our fuller checklist lives in how to spot a legit online clinic, and every program in our comparison is scored partly on exactly these signals — clinical review, medication transparency, and honest pricing.

The alternatives: branded, the new routes, and what's cheaper than you think

Because the compounded path narrowed, it's worth knowing that the FDA-approved options got more accessible at the same time — which changes the math that made compounding attractive in the first place.

Manufacturer direct and lower-cost branded options. The brand makers responded to the demand (and to the compounding competition) with lower-cost, direct-to-patient ways to buy the FDA-approved drugs, often for self-pay patients at prices far below the old list price. For many people, the gap between a legitimate compounded price and a manufacturer direct price has narrowed enough that the FDA-approved product — with its oversight, consistency and fixed-dose pens — is the better overall value. Always compare current numbers.

The arrival of the pill. There are now FDA-approved oral GLP-1 options too, which widen the legitimate menu further. Our guide to the GLP-1 weight-loss pill covers oral semaglutide and orforglipron (Foundayo), both FDA-approved, for people who'd rather not inject.

Insurance and Medicare. Coverage is uneven, but it's worth checking rather than assuming. Some plans cover branded GLP-1s with prior authorization, manufacturer savings cards can cut costs sharply when coverage comes through, and there are newer lower-cost routes to the original branded drugs worth checking on medicare.gov if you're eligible. Our complete guide walks through the cost picture in depth.

The point isn't that compounded is always wrong — it's that the two things that made it compelling (dramatically lower price, and being the only available option during the shortage) have both weakened. The shortage is over, and the price gap has shrunk. Run the current numbers for your situation before you assume compounded is the deal it was in 2023.

Red flags vs green flags: a quick reference

When you're staring at a compounded-GLP-1 offer and trying to decide in five minutes, this is the scan to run. None of the green flags guarantee a program is perfect, and a single red flag is often enough to walk away.

Walk away if you see (red flags)

• "No prescription needed" or a prescription "guaranteed" before any real medical review. The single brightest red line.
• "Research purposes only" / "not for human consumption" anywhere near the product. That's not medicine; it's unregulated material.
• They won't name the pharmacy that fills your medication, or you can't verify its license with a state board.
• Prices that are implausibly low with heavy pressure to prepay many months up front.
• No clear way to reach a licensed clinician about side effects or dosing.
• Vague or evasive answers about why they can legally compound it for you now that the shortage is over.

Reassuring signs (green flags)

• A genuine medical intake reviewed by a licensed prescriber, with a real person you can reach.
• A named, state-licensed pharmacy you can verify — ideally with a clear 503A patient-specific basis explained to you.
• Clear, unambiguous dosing instructions in a format you're comfortable measuring.
• Honest, itemized pricing with no high-pressure prepay trap, and a straight answer on what happens if supply or rules change.
• They also offer FDA-approved options (branded or the new pills), so you're not locked into one contested product.
• Transparency about what compounded is — including that it's not FDA-approved — rather than implying it's identical to the brand.

Run that scan before you buy. A program that clears the green-flag list and trips none of the red flags is the kind worth considering; one that trips even a couple of red flags is telling you to keep looking, no matter how good the price looks.

What this means for the online programs you're comparing

Most of the telehealth weight-loss programs people compare — including many we review — built their businesses on compounded GLP-1s during the shortage. So the obvious question is: what does the end of the exemption mean for them, and how should it change how you read their offers?

A compounded-only program is carrying more risk than it was. A program that sells only compounded GLP-1s, at a flat low price, to everyone, is operating the exact model that's under the most pressure. That doesn't automatically make it illegitimate — it may be using a real 503A pathway and careful pharmacies — but it does mean its core offering sits on contested ground. When you compare programs now, a provider that also offers the FDA-approved branded drugs, or has a clear, defensible compounding rationale, is on firmer footing than one betting entirely on cheap compounded copies.

Read medication claims more carefully. "GLP-1 from $X/month" tells you less than it used to. Ask: is that compounded or branded? If compounded, through what legal basis — a genuine patient-specific compound, or a mass-market "personalized" formula? Which pharmacy, and is it a licensed 503A? A program that answers those clearly is one you can trust more than one that keeps the details vague. This is why our reviews score medication transparency and clinical legitimacy as their own factors, not just price.

Flexibility is now a feature, not a nicety. Given the legal pressure, a program that can move you between compounded and branded — or that offers the new oral options — protects you against your specific product becoming unavailable. A program that can only offer one contested thing leaves you exposed if that thing goes away. When you read our ranked comparison, the programs that keep multiple legitimate paths open are better positioned for exactly this reason.

Cheapest is no longer automatically best. The whole premise of chasing the lowest compounded price assumed the price gap was huge and the supply was stable. Both have weakened. A program that's a little more expensive but offers FDA-approved options, real clinical support and honest medication disclosure may now be the better long-term bet than the rock-bottom compounded-only option — which is the lens our complete guide and scoring methodology apply. Price still matters; it just isn't the only thing that does, and in 2026 it's a weaker tiebreaker than it used to be.

If you take one thing from this section into your program comparison: the right question is no longer "who's cheapest on compounded," but "who offers a legitimate, stable, well-supported path to an effective GLP-1 for my situation." Sometimes that's still a compounded program with a solid 503A basis. Increasingly, it's one that gives you the FDA-approved options too.

A plain-language glossary

The compounding debate is thick with terms that get used loosely and cause half the confusion. Here are the ones that actually decide the answer.

• Compounding: a licensed pharmacy preparing a customized medication, rather than dispensing a mass-manufactured product. Legitimate and long-standing — but tightly limited when it comes to copying approved drugs.
• 503A pharmacy: a traditional compounding pharmacy that prepares a medication for a specific, named patient in response to an individual prescription. The main remaining legal route for a compounded GLP-1.
• 503B outsourcing facility: a larger facility that compounds in bulk, often without patient-specific prescriptions, under stricter manufacturing rules and a limited list of permitted bulk substances. Largely closed off for GLP-1s post-shortage.
• Shortage list (drug shortages database): the FDA's official list of drugs in shortage. While a drug is on it, compounding copies is broadly permitted; when it comes off, that permission ends. The trigger for this entire story.
• "Essentially a copy": a compounded drug that's basically the same as a commercially available approved product. Compounding these is restricted — permitted only in narrow situations, and not simply to save money.
• 503B bulks list: the list of bulk drug substances that outsourcing facilities are allowed to compound from. The FDA proposed in 2026 to exclude semaglutide and tirzepatide from it — a pending further restriction.
• Personalization / patient-specific exception: the argument that a compounded product is a customized preparation a specific patient needs (not just a copy), which can justify 503A compounding — legitimate with a real clinical reason, contested when used as a mass-market workaround.
• Salt form: a chemical variant of the active ingredient. Some compounded products have used salt forms (like semaglutide sodium) that aren't the same as what's in the approved drug — an FDA concern.
• 503A vs 503B, the one-liner: 503A = one pharmacist, one patient, one prescription; 503B = a facility making batches. For a compounded GLP-1 in 2026, the legitimate route is 503A patient-specific.

Frequently asked questions

Is compounded semaglutide legal in 2026?

In narrow cases, yes; broadly, no longer. The shortage-based permission that made cheap mass-market compounded semaglutide widely legal ended when the FDA declared the semaglutide shortage resolved in February 2025. A licensed 503A pharmacy can still compound it for an individual patient with a valid prescription when there's a genuine clinical reason the FDA-approved product can't meet — but "it's cheaper" is not a qualifying reason, and the mass-market model many telehealth sites still use relies on a contested legal argument the FDA is actively challenging.

Is compounded tirzepatide legal in 2026?

The same rules apply as for semaglutide, and tirzepatide's timeline ran slightly earlier: the FDA declared the tirzepatide shortage resolved in December 2024, ending the shortage-based basis for compounding it. Legitimate 503A patient-specific compounding with a documented clinical need remains possible; broad, cheap, one-formula-for-everyone compounding lost its clear legal footing.

Did the FDA ban compounded semaglutide?

Not with a single "ban." What happened is subtler and more important: the FDA resolved the shortage, which removed the legal basis that had allowed widespread compounding. Compounding itself remains legal in its traditional, patient-specific form. So it's less a ban than the expiration of a temporary permission — plus a proposed 2026 rule that would further restrict the bulk-compounding route.

Can I still get compounded semaglutide online?

Often, yes — but what you're being offered varies enormously in how legitimate it is. Some programs use a genuine 503A patient-specific pathway; some lean on a contested "personalization" argument; some sell non-compliant or unsafe products. Availability is not the same as legitimacy. Vet the program hard: confirm a real prescription and clinician, verify the pharmacy's license with the state board, and avoid anything sold with no prescription or as "research only."

Why is compounded semaglutide still being advertised everywhere if the shortage ended?

Three reasons: some operators pivoted to the narrow patient-specific "personalization" argument to keep going; some are continuing in a gray zone betting that enforcement lags the rule; and some are selling outright non-compliant products. The ads look the same as they did during the shortage, but the legal reality underneath has changed — which is exactly why you have to look past the marketing.

Is "personalized" compounded semaglutide (with B12 added) legal?

It can be legitimate when there's a real, documented clinical reason a specific patient needs a customized formulation — that's what the 503A exception is for. But adding a trivial ingredient like B12 to the same formula sold to hundreds of thousands of identical customers is a much weaker version of that argument, and the FDA has signaled it doesn't view trivial tweaks or lower price as legitimate grounds. Treat mass-market "personalized" offers as a contested legal position, not a settled green light.

What's the difference between 503A and 503B compounding?

A 503A pharmacy prepares a customized medication for a specific, named patient in response to an individual prescription. A 503B outsourcing facility manufactures compounded drugs in bulk, often without patient-specific prescriptions, under stricter manufacturing rules and a limited list of permitted bulk substances. Post-shortage, the narrow legal route for a compounded GLP-1 runs through 503A patient-specific compounding; the 503B bulk route is largely closed and the FDA has proposed to restrict it further.

Is compounded semaglutide safe?

It can be, from a reputable pharmacy — but it isn't FDA-approved and doesn't go through premarket review for safety, effectiveness or quality, so safety depends entirely on the specific pharmacy. The FDA has documented real harms, including dosing errors (people overdosing when drawing up from vials) and concerns about different salt forms and mislabeled sourcing. The branded products have oversight and fixed-dose pens that compounded products generally lack.

Is compounded semaglutide the same as Wegovy or Ozempic?

No. It uses the same active ingredient (semaglutide), but it's prepared by a compounding pharmacy rather than manufactured as an FDA-approved product, it has no clinical trials of its own, its quality and concentration vary by pharmacy, and it is not a "generic" — no FDA-approved generic of Wegovy or Ozempic exists. It can be a reasonable option in the right circumstances, but it is not interchangeable with the branded drug.

Are "research peptides" a legal way to get cheaper semaglutide?

No. Products sold "for research purposes only" or "not for human consumption" are not a budget version of the medication — they're unregulated material of unknown identity, purity and sterility, with no oversight and no recourse if something goes wrong. Using them as medicine is both outside the law and genuinely dangerous. Avoid them entirely.

Could my compounded-GLP-1 program suddenly shut down?

It's a real possibility for programs relying on the contested mass-market model. With the shortage over, a pending FDA proposal to restrict bulk compounding, and courts siding with the FDA so far, the pressure on that business model is increasing. For a chronic-condition medication you may take long-term, building your plan on a contested, shrinking legal basis is a risk worth weighing against the stability of the FDA-approved options.

Does the legality vary by state?

The core federal framework (503A vs 503B, the shortage rules, the proposed bulks-list change) is national, but pharmacy licensing and oversight are handled at the state level, and state boards of pharmacy have issued their own compliance guidance. Practically, that means you should verify any pharmacy's license and standing with the relevant state board, and be aware that enforcement activity can differ from state to state even when the federal rules are the same.

How can I check the current status myself?

Two authoritative bookmarks: the FDA's drug shortages database (to confirm whether a drug is in shortage — the trigger for broad compounding), and the FDA's compounding Q&A (for the framework). Because this area is moving quickly, check current status directly rather than trusting a months-old article or forum post — including this one.

Is semaglutide still in shortage in 2026?

No. The FDA declared the semaglutide shortage resolved in February 2025 (tirzepatide in December 2024), and that resolution has held — the drugs are not on the current shortage list. Because the shortage is what legally enabled broad compounding, its end is the single fact driving everything in this guide. Always confirm current status on the FDA's drug shortages database, since shortage determinations can in principle change.

Can my doctor still prescribe compounded semaglutide?

A clinician can still write a prescription that a 503A pharmacy fills, but only within the narrow legal lane: a patient-specific preparation with a genuine, documented clinical reason the FDA-approved product can't meet — not simply because it's cheaper. A responsible prescriber will be able to explain that rationale. If a program issues compounded prescriptions to essentially everyone at a flat price, that's the contested mass-market model, not ordinary individualized prescribing.

What happens to my existing compounded prescription?

An existing prescription doesn't make an otherwise non-compliant product retroactively fine, but the bigger practical risk is supply: a program relying on the contested model may change its formula, raise prices, or stop offering compounded altogether as rules tighten. If you're mid-treatment, the smart move is to understand your program's legal basis now and have a legitimate branded backup already priced, so an interruption to your GLP-1 doesn't catch you flat-footed.

Did Novo Nordisk and Eli Lilly fight the compounders?

The brand manufacturers have been active in protecting their approved products, and the compounding industry's association challenged the FDA's shortage-resolution decisions in court. The courts sided with the FDA, and the wind-down deadlines held; further litigation has targeted the medical-necessity basis some compounders use. The overall direction across these disputes has favored tighter limits on compounded copies, not broader access.

Is compounded semaglutide actually cheaper than branded now?

Sometimes, but the gap narrowed. During the shortage, compounded was dramatically cheaper and often the only available option. Since then, the brand makers added lower-cost direct-to-patient self-pay routes, and compounded carries new legal and supply risk. For some people compounded is still cheaper month to month; for others, once consistency and the risk of a program folding are factored in, the FDA-approved drug at a manufacturer-direct price is the better value. Price your own situation with current numbers rather than assuming.

Is microdosing compounded GLP-1 legal?

"Microdosing" (using smaller-than-standard doses) doesn't change the underlying legal picture. If the product is a compounded copy obtained without a legitimate patient-specific basis, using less of it doesn't make it compliant; if it's a genuine 503A preparation for a documented clinical reason, the dose is a clinical matter between you and your prescriber. The legality hinges on the pathway and the clinical justification, not the size of the dose.

What's the one question to ask a program before buying compounded?

"Now that the shortage is over, what's the legal basis for compounding this for me, and which licensed pharmacy fills it?" A legitimate program answers clearly — a real patient-specific rationale and a named, verifiable 503A pharmacy. Evasion, a sales-y non-answer, or "don't worry about it" is your cue to walk. One good question separates most of the solid programs from the shaky ones.

Final verdict & next steps

The era of cheap, no-questions-asked compounded GLP-1s is over, and it isn't coming back in that form. The shortage that created it has been resolved, the legal exemption that permitted it has expired, courts have backed the FDA, and a further restriction is pending. Compounding didn't become illegal — the narrow, legitimate, patient-specific version remains — but the mass-market model that put compounded semaglutide in everyone's feed now rests on a contested argument that regulators and courts are steadily tightening.

For most people, that reshapes the decision. The two forces that made compounded compelling — rock-bottom price and being the only way to get the drug — have both weakened, while the FDA-approved options have become more accessible and now include pills. So the honest default in 2026 is to start with the legitimate, FDA-approved route and the most affordable legal way to reach it, and to consider compounded only through a genuine 503A pathway when you have a real clinical reason the commercial product can't meet.

Your next steps:

• Check the current FDA shortage status before assuming anything — the drug shortages database is the source of truth.
• Price the FDA-approved drug for your situation — insurance, manufacturer savings, direct-to-patient options, and the new pill — before defaulting to compounded. Our complete guide and ranked comparison show the real numbers.
• If you do consider compounded, vet it hard: real prescription, named and state-licensed pharmacy, a genuine clinical rationale, clear dosing, and honest pricing. Our legit-clinic checklist is built for this.
• Talk to a licensed clinician about which route fits your health and your budget — and treat any "no prescription needed" offer as the exit sign it is.